Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/21/2024 | $21.00 → $25.00 | Buy → Neutral | Compass Point | |
| 11/8/2024 | $56.00 | Neutral | JP Morgan | |
| 10/24/2024 | $120.00 → $125.00 | Underweight | Wells Fargo | |
| 10/24/2024 | $236.00 → $238.00 | Hold | Truist | |
| 10/24/2024 | $165.00 → $195.00 | Hold | Jefferies | |
| 10/24/2024 | $245.00 → $255.00 | Neutral | Cantor Fitzgerald | |
| 10/24/2024 | $230.00 → $250.00 | Neutral | Goldman | |
| 10/24/2024 | $236.00 → $249.00 | Outperform | RBC Capital Mkts |
Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended
ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer ("CEO") effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab. "Sean's appointment serves as a significant step towards further rea
Fort Lauderdale, FL, Sept. 05, 2024 (GLOBE NEWSWIRE) -- MARA Holdings Inc. (NASDAQ:MARA) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, today announced the appointment of Janet George and Barbara Humpton to its board of directors, and announced the appointment of current board member Doug Mellinger as lead independent director, effective September 1, 2024. Ms. George and Ms. Humpton replace Kevin DeNuccio and Said Ouissal, who have stepped down from the board, effective September 1, 2024, as part of a planned transition. Ms. George and Ms. Humpton were selected to join MARA's board for their exceptional leadership and
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Occidental (NYSE:OXY) today announced its third quarter 2024 financial results. The earnings release and accompanying financial schedules can be accessed via the Investor Relations section of the company's website, oxy.com. The earnings release is also available on the U.S. Securities and Exchange Commission's website at sec.gov. The company will hold a conference call to discuss the results on Wednesday, November 13, 2024, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at oxy.com/investors. Participants may pre-register for the conferen
Fort Lauderdale, FL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a letter to shareholders, MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, today announced that its third quarter 2024 financial results are now available. Investors are invited to access the third quarter 2024 shareholder letter at MARA's website at ir.mara.com. A copy of the letter will also be furnished to the Securities and Exchange Commission on a Form 8-K. MARA will hold a webcast and conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) today to discuss these financial results. To register to participate in th
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct
SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)
SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)
SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)
4 - MARA Holdings, Inc. (0001507605) (Issuer)
4 - MARA Holdings, Inc. (0001507605) (Issuer)
4 - IGM Biosciences, Inc. (0001496323) (Issuer)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to
https://x.com/elonmusk/status/1816478001884004816https://x.com/elonmusk/status/1815907844434112999
8-K - MARA Holdings, Inc. (0001507605) (Filer)
8-K - MARA Holdings, Inc. (0001507605) (Filer)
144 - Tesla, Inc. (0001318605) (Subject)
Proceeds to be used primarily to acquire bitcoin and repurchase existing convertible notes due 2026 Fort Lauderdale, FL, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ:MARA) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support the energy transformation, today announced the closing on November 20, 2024 of its offering of 0.00% convertible senior notes due 2030 (the "notes"). The aggregate principal amount of the notes sold in the offering was $1 billion, which includes $150 million aggregate principal amount of notes issued pursuant to an option to purchase, within a 13-day period beginning on, and including, the date on which the notes w
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB, the ", Company", )), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. Piper Sandler 36th Annual Healthcare Conference Presentation Details Presentation Time Wednesday, December 4 at 4:30 p.m. ET Presenters Sean Fu,
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (NASDAQ:SDA), a leading innovator in cloud-based B2B auto services and auto e-insurance in China, is pleased to announce its inclusion in the NASDAQ Golden Dragon China Index, marking an important milestone in the Company's growth journey. The NASDAQ Golden Dragon China Index is a benchmark for tracking Chinese companies listed on U.S. exchanges, offering investors a window into the dynamic growth opportunities within China's economy, particularly in sectors like digital services, technology, new consumer markets, and clean energy. This prestigious index includes leading Chinese companies like Alibaba (NYSE:BABA), JD.com (
Compass Point downgraded MARA Holdings Inc. from Buy to Neutral and set a new price target of $25.00 from $21.00 previously
JP Morgan resumed coverage of Occidental Petro with a rating of Neutral and set a new price target of $56.00
Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $125.00 from $120.00 previously